Genentech, a member of the Roche Holding AG (RHHBY), said on Friday that the U.S. Food and Drug Administration has approved the combination of Venclexta plus acalabrutinib for the treatment of previously untreated adults with chronic lymphocytic leukemia (CLL).
The approval was based on results from the Phase III AMPLIFY study which showed that the combination regimen reduced the risk of disease progression or death by 35% versus chemoimmunotherapy.
Venclexta is already approved for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and in combination regimens for newly diagnosed AML patients aged 75 or older, or those ineligible for standard chemotherapy.
Venclexta is developed by AbbVie and Genentech, and is jointly commercialized in the United States and marketed by AbbVie outside the U.S.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.